Effect of glucagon-like peptide-1 (7-37) on beta-cell function after islet transplantation in type 1 diabetes

Michelle Fung, David Thompson, R. Jean Shapiro, Garth L. Warnock, Dana Andersen, Dariush Elahi, Graydon S. Meneilly

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Islet transplantation can improve glycemic control in patients with type 1 diabetes and reduce or eliminate the need for insulin. Glucagon-like peptide-1 (GLP-1) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion, and has a trophic effect on beta-cells. We evaluated the effect of GLP-1 on insulin secretion after islet transplantation. Patients underwent hyperglycemic glucose clamp studies 1 month after their last transplant. GLP-1 was infused during the second hour of the hyperglycemic clamp. Results were compared to normal control subjects and patients with type 2 diabetes who underwent an identical hyperglycemic clamp. First phase insulin release was absent in patients, while second phase insulin was not significantly reduced (control: 118 ± 29 pM; type 2 diabetes: 68 ± 20 pM; transplant: 99 ± 18 pM, p = ns for all). GLP-1 had a significant incretin effect on transplanted islets but the response was less than controls (control: 2108 ± 344 pM; type 2 diabetes: 929 ± 331 pM; transplant: 329 ± 112 pM, p <0.0001 control versus transplant). Islet transplant patients had no evidence of resistance to insulin mediated glucose disposal. We conclude that transplanted islets retain the ability to respond to GLP-1.

Original languageEnglish (US)
Pages (from-to)189-193
Number of pages5
JournalDiabetes Research and Clinical Practice
Volume74
Issue number2
DOIs
StatePublished - Nov 2006
Externally publishedYes

Fingerprint

Islets of Langerhans Transplantation
Glucagon-Like Peptide 1
Type 1 Diabetes Mellitus
Insulin
Transplants
Type 2 Diabetes Mellitus
Gastrointestinal Hormones
Incretins
Glucose
Glucose Clamp Technique
Insulin Resistance
glucagon-like peptide 1 (7-37)

Keywords

  • GLP-1
  • Incretin
  • Islet transplantation
  • Type 1 diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Effect of glucagon-like peptide-1 (7-37) on beta-cell function after islet transplantation in type 1 diabetes. / Fung, Michelle; Thompson, David; Shapiro, R. Jean; Warnock, Garth L.; Andersen, Dana; Elahi, Dariush; Meneilly, Graydon S.

In: Diabetes Research and Clinical Practice, Vol. 74, No. 2, 11.2006, p. 189-193.

Research output: Contribution to journalArticle

Fung, Michelle ; Thompson, David ; Shapiro, R. Jean ; Warnock, Garth L. ; Andersen, Dana ; Elahi, Dariush ; Meneilly, Graydon S. / Effect of glucagon-like peptide-1 (7-37) on beta-cell function after islet transplantation in type 1 diabetes. In: Diabetes Research and Clinical Practice. 2006 ; Vol. 74, No. 2. pp. 189-193.
@article{0340186c3aa147079764be3700b70d18,
title = "Effect of glucagon-like peptide-1 (7-37) on beta-cell function after islet transplantation in type 1 diabetes",
abstract = "Islet transplantation can improve glycemic control in patients with type 1 diabetes and reduce or eliminate the need for insulin. Glucagon-like peptide-1 (GLP-1) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion, and has a trophic effect on beta-cells. We evaluated the effect of GLP-1 on insulin secretion after islet transplantation. Patients underwent hyperglycemic glucose clamp studies 1 month after their last transplant. GLP-1 was infused during the second hour of the hyperglycemic clamp. Results were compared to normal control subjects and patients with type 2 diabetes who underwent an identical hyperglycemic clamp. First phase insulin release was absent in patients, while second phase insulin was not significantly reduced (control: 118 ± 29 pM; type 2 diabetes: 68 ± 20 pM; transplant: 99 ± 18 pM, p = ns for all). GLP-1 had a significant incretin effect on transplanted islets but the response was less than controls (control: 2108 ± 344 pM; type 2 diabetes: 929 ± 331 pM; transplant: 329 ± 112 pM, p <0.0001 control versus transplant). Islet transplant patients had no evidence of resistance to insulin mediated glucose disposal. We conclude that transplanted islets retain the ability to respond to GLP-1.",
keywords = "GLP-1, Incretin, Islet transplantation, Type 1 diabetes",
author = "Michelle Fung and David Thompson and Shapiro, {R. Jean} and Warnock, {Garth L.} and Dana Andersen and Dariush Elahi and Meneilly, {Graydon S.}",
year = "2006",
month = "11",
doi = "10.1016/j.diabres.2006.03.022",
language = "English (US)",
volume = "74",
pages = "189--193",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Effect of glucagon-like peptide-1 (7-37) on beta-cell function after islet transplantation in type 1 diabetes

AU - Fung, Michelle

AU - Thompson, David

AU - Shapiro, R. Jean

AU - Warnock, Garth L.

AU - Andersen, Dana

AU - Elahi, Dariush

AU - Meneilly, Graydon S.

PY - 2006/11

Y1 - 2006/11

N2 - Islet transplantation can improve glycemic control in patients with type 1 diabetes and reduce or eliminate the need for insulin. Glucagon-like peptide-1 (GLP-1) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion, and has a trophic effect on beta-cells. We evaluated the effect of GLP-1 on insulin secretion after islet transplantation. Patients underwent hyperglycemic glucose clamp studies 1 month after their last transplant. GLP-1 was infused during the second hour of the hyperglycemic clamp. Results were compared to normal control subjects and patients with type 2 diabetes who underwent an identical hyperglycemic clamp. First phase insulin release was absent in patients, while second phase insulin was not significantly reduced (control: 118 ± 29 pM; type 2 diabetes: 68 ± 20 pM; transplant: 99 ± 18 pM, p = ns for all). GLP-1 had a significant incretin effect on transplanted islets but the response was less than controls (control: 2108 ± 344 pM; type 2 diabetes: 929 ± 331 pM; transplant: 329 ± 112 pM, p <0.0001 control versus transplant). Islet transplant patients had no evidence of resistance to insulin mediated glucose disposal. We conclude that transplanted islets retain the ability to respond to GLP-1.

AB - Islet transplantation can improve glycemic control in patients with type 1 diabetes and reduce or eliminate the need for insulin. Glucagon-like peptide-1 (GLP-1) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion, and has a trophic effect on beta-cells. We evaluated the effect of GLP-1 on insulin secretion after islet transplantation. Patients underwent hyperglycemic glucose clamp studies 1 month after their last transplant. GLP-1 was infused during the second hour of the hyperglycemic clamp. Results were compared to normal control subjects and patients with type 2 diabetes who underwent an identical hyperglycemic clamp. First phase insulin release was absent in patients, while second phase insulin was not significantly reduced (control: 118 ± 29 pM; type 2 diabetes: 68 ± 20 pM; transplant: 99 ± 18 pM, p = ns for all). GLP-1 had a significant incretin effect on transplanted islets but the response was less than controls (control: 2108 ± 344 pM; type 2 diabetes: 929 ± 331 pM; transplant: 329 ± 112 pM, p <0.0001 control versus transplant). Islet transplant patients had no evidence of resistance to insulin mediated glucose disposal. We conclude that transplanted islets retain the ability to respond to GLP-1.

KW - GLP-1

KW - Incretin

KW - Islet transplantation

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=33751091296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751091296&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2006.03.022

DO - 10.1016/j.diabres.2006.03.022

M3 - Article

C2 - 16621111

AN - SCOPUS:33751091296

VL - 74

SP - 189

EP - 193

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 2

ER -